BMC Infectious Diseases

, 19:966 | Cite as

Risk factors of 90-day rehospitalization following discharge of pediatric patients hospitalized with mycoplasma Pneumoniae pneumonia

  • Le Wang
  • Zhishan Feng
  • Jinfeng Shuai
  • Jianhua LiuEmail author
  • Guixia LiEmail author
Open Access
Research article
Part of the following topical collections:
  1. Bacterial and fungal diseases



Among pediatric patients hospitalized for Mycoplasma pneumoniae pneumonia (MPP), the risk factors for 90-day readmission after discharge is undefined.


We conducted a retrospective observational study of patients <14 years of age who were discharged with a diagnosis of MPP between January 2016 and February 2017. We collected clinical, laboratory and radiographic variables at the time of initial admission. We assessed pneumonia-related readmission within 90-day after discharge. Risk factors independently associated with rehospitalization were identified using multiple logistic regression models.


Of the 424 MPP hospitalizations, 48 (11.3%) were readmitted within 90 days and were mainly diagnosed with pneumonia. Patients with younger age or coinfection with influenza A were more likely to be readmitted. In addition, compared with children without readmission, the readmission ones showed different clinical and laboratory characteristics at the index hospital admission. Multiple logistic regression analysis identified age (OR 0.815, 95%CI 0.706–0.940) and body temperature (OR 0.659, 95%CI 0.518–0.839) were significantly associated with lower risk of 90-day readmission. Coinfection with influenza was independently associated with a greater likelihood of 90-day readmission (OR 4.746, 95%CI 1.191–18.913).


Readmission after MPP are common and is related to patients’ age, body temperature and influenza A coinfection during initial hospital stay, indicating potential targets could be noticed to reduce the rehospitalization after pediatric MPP.


MPP Rehospitalization Children 



Community acquired pneumonia

GeXP assay

GenomeLab Genetic Analysis System

MP or M. pneumoniae

Mycoplasma pneumoniae


Reverse transcription polymerase chain reaction


Readmission of patients initially hospitalized for community acquired pneumonia (CAP) is relatively common [1, 2, 3]. Both of preventable and non-preventable risk factors have been explored, but the main participants in these studies were the elderly and patients with multiple comorbidities, not children [4, 5, 6, 7].

The previous three studies described 14 days [8], 30 days [9] readmission rates (range of 1.5–8%) for children with pneumonia or lower respiratory infections (LRIs) [10]. In these studies, one of the consistent identified risk factors was chronic medical conditions. But in fact, a large number of children who are rehospitalized are caused by acute diseases [11]. If patients with chronic conditions are excluded, the difficulty is to detect readmission risk factors associated with the current acute infection. In addition, children with LRIs, a relatively broad diagnosis, or pneumonia with an underlying chronic illness may bring compounding factors conferring susceptibility for readmission. A promising approach to resolve this problem is to narrow down study sample according to the pathogenic or clinical features, such as Mycoplasma pneumoniae pneumonia (MPP), which accounts for up to 40% pediatric CAP [12], and its diagnosis is based on etiology and clinical evidence, thereby elevating the power to detect readmission risk factors associated with the current acute infections. We hypothesized that MPP children may have different characteristic during the first hospital stay between patients with and without readmission. This study was therefore conducted to enroll pediatric MPP patients without other underlying chronic diseases.

Our aims were to (1) describe the incidence and type of readmission after MPP discharge, (2) investigate the differences between patients with and without readmission at the initial hospital stay, (3) examine the risk factors for 90-day pneumonia-related rehospitalization.

Material and methods

Study design

This retrospective, observational study was conducted at Children’s Hospital of Hebei Province, a 1200-bed teaching hospital in Hebei Province (northern China) that serves a population of 70,000,000 inhabitants, including 18.5% children. Patients with a discharge diagnosis of MPP were evaluated. The project was approved by the ethics review board of the hospital. Because data in this report were collected from inpatient electronic medical records, there was no need to collect new specimens or the corresponding written informed consent.

Study sample

Children ≤14 years of age who were admitted to Children’s Hospital of Hebei Province with a diagnosis of MPP from January 2016, to February 2017, were consecutively enrolled into the study. The diagnosis of MPP needs to meet the following first 2 points plus either third or fourth point [13]: 1) a new infiltrate on a chest radiograph; 2) fever, cough and abnormal lung auscultation; 3) positive serology laboratory results specific MP antibody titer≥1:160 detected by a micro-particle agglutination test [14]; 4) positive PCR laboratory results, MP-DNA positive detected in sputum, nasopharyngeal aspirate or bronchoalveolar lavage fluid (BALF) by PCR [15]. Patients were excluded from the study if they were known to be chronically immunosuppressed, or with chronic cardiopulmonary conditions or had been hospitalized for the previous 14 days. If a patient had more than one episode of pneumonia during the index hospitalization, only the first one was included in the analysis.

Data and specimen collection

The following patient characteristics were evaluated: age, sex, signs and symptom before admission (wheezing, cough and diarrhea). The laboratory data and radiological findings were also measured and retrospectively investigated from inpatient electronic medical records system. Clinical symptoms included wheezing, cough and diarrhea. Ill day and febrile day before admission, hospital days, febrile day and readmission rate were also recorded. The time frame of readmission was set as 90-day from original discharge. Body temperature was examined at the beginning of admission and every 8 h thereafter. A febrile day was defined as the body temperature exceeded 38.0 °C at least once [16].

Patients were asked to cough, and the expectorated sputum was collected. If the child is too young to cough, a sterile negative pressure suction catheter is applied to obtain the oropharyngeal suction (OPS). The storage, transportation and nucleic acid extraction procedure were reported elsewhere [17]. The paired serum samples were taken at the presentation of pneumonia and at least 7 days after the first collection of serum. The serum was obtained from 2 mL whole blood by the separation gel tube.

Detection of MP-DNA and MP-antibody

The GeXP assay (GenomeLab GeXP Genetic Analysis System) was performed on all specimens for the 13 type/subtypes of common respiratory pathogens including M. pneumoniae. The multiplex-PCR was performed as previously described elsewhere [18]. The bacteria infection was examined by standard culture methods from sputum specimens [19]. The determination of MP-specific antibody was performed using a commercially available micro-particle agglutination test Serodia-MycoII kit (Fujirebio, Tokyo, Japan) [14]. Diagnosis criteria were defined as ≥4-found rising for paired sera or single serum of titer ≥1:160 [15].

Statistical analysis

The chi-squared test was used to compare categorical variable in subgroups. And for those continuous variables with normal and non-normal distributions, mean or median values were compared using the t test or Mann-Whitney U test. SPSS 19.0 statistics package (SPSS Inc., Chicago, USA) software was used for all statistical analysis. p < 0.05 was considered statistically significant.


Patients enrollment and readmission diagnoses

During the study period, 432 inpatients met our study eligibility criteria for MPP: 8 patients were excluded due to the missing sex, age or diagnostic data, and 368 patients were not readmitted to hospital within 90 days (Fig. 1). Of the 56 patients who were readmitted in 90 days, 8 were diagnosed with pneumonia-unrelated diseases including epilepsy, encephalitis, carditis and arthritis. Therefore, 48 (11.3%) children were readmitted due to pneumonia-related diseases in 90 days of initial MPP discharge. Of the 48 re-admitted cases, 17 (35.4%) were reinfected with MP, 23 (47.9%) were negative for MP, and 8 (16.7%) did not receive pathogen detection test. The most common cause of readmission was pneumonia (47.9%), followed by bronchial pneumonia (45.8%) bronchitis (4.2%) and one (2.1%) refractory mycoplasma pneumoniae pneumonia (RMPP) (Table 1). Among the enrolled 424 patients, there were 23 cases were detected to be positive by PCR alone, 129 were serology alone (with 6 cases as seroconversion and 123 cases as single high titer) and 272 were positive by both PCR and serology assays.
Fig. 1

Patient flow chart, the index admission and 90-days readmission. The diagnosis of pneumonia-unrelated readmission included: 3 epilepsy, 2 encephalitis, 2 carditis and 1 arthrosynovitis cases

Table 1

The diagnosis of 90-days pneumonia-related readmission

Readmission diagnosis












Refractory Mycoplasma pneumoniae pneumonia



Characteristics of children

Demographic characteristics included age (median age 4.5, range in 0.1–13) and gender (238 boys and 186 girls). As shown in Table 2, patients who were readmitted in 90 days were significantly younger than those without readmission (median age: 2 v.s. 4.7 years, p < 0.001) and were more likely to show wheezing symptoms (p < 0.001), as well as a lower body temperature on admission (p < 0.001), shorter febrile days during hospital stay (p < 0.001). Similarly, more patients with readmission showed normal (p = 0.009) or light diffuse shadowing (p = 0.030) radiological findings. CRP, LDH, HBDH and neutrophil percentage levels were lower, but the percentage of lymphocyte was significantly greater (all p < 0.05) (Table 3).
Table 2

Patient characteristic on index visit are different between children with and without readmission


With readmission

Without readmission


n = 48

n = 376


Sex (Male)

31 (64.6%)

211 (56.1%)


Age (Year)

2 (1–4.6)

4.7 (2.5–7)


Before and after admission

Ill day before admission

10 (5.5–15)

8 (6–14)


Febrile day before admission

3 (0–8.5)

6 (3–10)


Body Temperature on admission

38.5 (36–39.4)

39.3 (38.6–39.8)


Hospital day

9 (7–15)

10 (7–14)


Febrile day after admission

1 (0–3)

2 (0–4)


Clinical manifestation at presentation

Wheezing day

5 (3–8)

3 (2–10)


Cough day

9 (4.5–15)

7 (5–12)


Diarrhea day

6 (5–7)

2.5 (2–3)


Radiographic finding


11 (22.9%)

38 (10.1%)


Light diffuse shadowing

15 (31.2%)

68 (18.1%)


16 (33.3%)

169 (44.9%)

Pleural effusion

5 (10.4%)

75 (19.9%)

Severity on admission

ICU admission

7 (14.6)

26 (6.9%)


Mechanical ventilation

3 (6.3%)

13 (3.5%)


Data were shown in median (IQR) or N (%). Comparative analysis was performed using the Chi-Square or Mann-Whitney U test, as appropriate

aSeparately, p values are 0.009 for Normal group, 0.030 for Light diffuse shadowing group, 1.127 for Consolidation group, 0.112 for Pleural effusion group

Table 3

Different laboratory data on index hospitalization between patients with and without readmission

Laboratory data

With readmission

Without readmission


n = 48

n = 376

WBC (10^9/L)

8.6 (7.3,11.3)

9.9 (7.6, 13.2)


Neutrophil (%)

49.2 ± 17.5

55.6 ± 16.3


Lymphocyte (%)

40.4 ± 16.0

31.9 (21.3, 43.6)


Monocyte (%)

7.1 ± 2.6

6.6 (5.4–8.2)


CRP (mg/L)

4.2 (1.0, 11.4)

10.4 (1.4–30.0)



261.5 (228.7, 299.2)

290.0 (244.7–373.0)



211.5 (189.0, 236.2)

237.5 (201.7–296.0)


WBC White blood cell, LDH Lactatedehydrogenase, HBDH Hydroxybutyrate dehydrogenase, CRP C-reactive protein

Data were shown in mean ± SD or median (IQR)

Comparative analysis was performed using Chi-Square or Mann-Whitney U test

Coinfection pathogens

Coinfection was observed in 189 (44.6%) cases, and children infected with influenza A were more likely to be admitted again (p < 0.001, Table 4). Coinfection rates of other pathogens (rhinovirus, parainfluenza, influenza B, respiratory syncytial virus, adenovirus, coronavirus, human metapneumovirus, S. pneumoniae and human bocavirus) did not vary significantly between patients with and without rehospitalization.
Table 4

The coinfection pathogens in patients with 90-days readmission



Readmission cases




12 (15.0%)




5 (15.2%)


Influenza B


5 (17.2%)


Respiratory syncytial virus


1 (5.9%)




2 (13.3%)




1 (7.7%)


Human metapneumovirus


1 (7.7%)


Influenza A


6 (54.5%)


S. pneumoniae


1 (10.0%)


Human Bocavirus


0 (0.0%)


aThere are mixed infections with more than one pathogen, the total cases is not equal to 189. There are 155 cases of single pathogen coinfection, 30 cases of two pathogens, 4 cases of 3 pathogens

Multiple logistic regression analysis

Multiple logistic regression analysis identified age (OR 0.815, 95%CI 0.706–0.940) and body temperature (OR 0.659, 95%CI 0.518–0.839) during initial hospital stay were significantly associated with lower risk of 90-day readmission. Coinfection with influenza A at index admission was independently associated with a greater likelihood of 90-day readmission (OR 4.746, 95%CI 1.191–18.913) (Table 5).
Table 5

Stepwise logistic regression for the related factors associated with readmission

Positive Variables



95% CI








Influenza A coinfection





Body Temperature on admission






Generally, readmissions after pneumonia are common. In terms of safety and cost, it is important to assess the relationship between initial hospital stay and readmission outcomes [9, 20]. Although the investigation of risk factors is challenging, significant progress has been made on the elderly, that the readmission was found to be largely depends on the comorbidities and factors external to the patient [1, 2, 4, 21]. This has also been observed in children, and one of the identified risk factors is chronic medical conditions such as underlying pulmonary or cardiovascular disease [9, 10, 11]. To date, research on potential risk factors for readmission has hardly focused on current acute infections or specific pathogens. Because pneumonia is a complex heterogenous disease that can be caused by a variety of pathogens, 1) studying pneumonia patients with the same infectious pathogen can reduce heterogeneity, 2) exclusion of patients with underlying diseases can improve the ability to detect readmission risk factors associated with the current acute infections. Therefore, we investigated the rate of 90-day pneumonia-related readmission in hospitalized children with MPP who had no basal or chronic disease. After comparing the clinical information of the first hospitalization between patients who were readmitted and not readmitted to the hospital, we obtained the following findings: 1) 48 (11.3%) children were readmitted within 90 days of the first MPP discharge; 2) at the index hospital stay, readmission patients manifested different characteristics; 3) co-infection with influenza A increased the risk of 90-day readmission.

In this study, the readmission rate after MPP discharge was 11.6%. Pneumonia and bronchial pneumonia were the majority diagnoses on readmission. Nakamura et al. identified that 5.5% cases readmitted after LRI hospitalization, and the most common readmission diagnose was LRI (48.2%) [10]. Similar to the pattern observed by Neuman and colleagues, nearly half of the 8% of patients who were discharged from initial pneumonia hospitalization were also associated with pneumonia [9]. Previous work has shown that 30% pediatric readmissions are potentially preventable, especially the index admission and readmission are causally related [22]. This is one of the reasons we focus on pneumonia-related readmission. Meanwhile, we observed a trend in patients with relatively mild radiological symptoms and lower levels of acute inflammatory markers that are more likely to be rehospitalized. The cause of this phenomenon may be related to two points, including different host immunity and treatment strategies. First, clinical presentation depends on the host’s immune response, rather than direct microbial destruction during the progression of M. pneumoniae infection [23]. Patient with a reduced immune system, such as younger ones who have had less time to develop immunity, may be characterized by mild clinical symptoms but with a prolonged recovery period. Second, pediatricians will adopt different treatment strategies for patients with severe or mild symptoms. Patients at risk of readmission may receive different medication times due to M. pneumoniae virulence or host immune response.

In this present study, we found that influenza coinfection increased the risk of readmission, which is consistent with previous investigations of children with complicated pneumonia. William et al. found that although there was a trend to increase mortality, patients with flu coinfection were less likely to readmitted in 2 weeks readmission, [24]. Brogan et al. observed that children who were infected with influenza during the initial hospital stay had a higher rate of readmission than children who were not infected with influenza [25]. Regarding the elderly, researches show that influenza vaccination is associated with a lower likelihood of readmission [5, 26, 27]. In view of these findings, influenza vaccination should be promoted not only in pediatric hospitals at CAP discharge, but also for all people, particularly in high risk groups including children under 5 years old, and those with asthma. In addition, we observed that younger children are liable to readmit, which is consistent with previous findings, demonstrating a higher rate of readmission for children under 1 year of age [9, 28]. As explained by Gay JC et al., pneumonia in young patients usually has protracted and waning course, leading to structural lung damage or immune paresis and further pneumonia episodes [28]. Second, younger patients may be more prone to new infections due to higher exposure during nursery attendance and the previous lack of immunity to respiratory pathogens, which will be resulting in rehospitalization. Furthermore, Studies of children with asthma have found that the rate of readmission of children under 1 year of age in higher, further highlighting the need to improve inpatient decision-making for young patients.

To our knowledge, this is the first study to explore the factors of readmission for pediatric MPP patients. Further research in larger cohorts is needed to validate the data. Meanwhile, some questions remain to be answered: first, it has been reported that pneumonia attributed to potentially antibiotic-resistant bacteria is associated with an increased risk of readmission [21], we strongly felt that macrolide resistance has a role on the risk of readmission, but what is the role? Second, coinfection with influenza A will increase the risk of readmission, what is the underlying mechanism?


This study has several limitations. First, the sample size may be small because only 48 patients were rehospitalized within 90 days. Second, if the child is readmitted to another institution, we may underestimate the rate of readmission. Third, in the absence of the information after first discharge, the interference factor related to age may be introduced into this research, as the rehospitalization may be caused by a new infection during nursery attendance. Fourth, other clinical information to document severity is not included in the study, such as oxygen requirement, antibiotic or corticoid duration. Fifth, a potential limitation would be that the serological assays have a high false positive detection rate and it is difficult to obtain the second serum. In our report, only 6 children provided paired sera, and the other 123 patients (123/424, 29%) had positive serological results with only a single high titer, but the PCR results were negative. Last, although there were significant differences in CRP, LDH levels or patient characteristics between rehospitalized and non-rehospitalized patients, these factors cannot be controlled and of low value in clinical practice.


In conclusion, rehospitalization after MPP is relatively common and is related to patients’ age and co-infected pathogens. Careful attention to clinical variables may reduce the frequency of rehospitalization of pediatric patients after discharge on MPP.



We sincerely thank all the participants for their support. We also thank Dr. Sukun Lu and Lijie Cao from the No.2 Department of Respiratory, Children’s Hospital of Hebei Province, for their help to record the clinical information.

Authors’ contributions

LW performed the statistical analysis and drafted the manuscript. ZF participated in the validation. GL and JL participated in the design of the study. GL conceived of the study, and participated in its design and coordination, JS helped to draft the manuscript. All authors read and approved the final manuscript.


Not applicable.

Ethics approval and consent to participate

The protocols used in this retrospective study was reviewed and approved by the institutional review board of Children’s Hospital of Hebei Province. Because there was no need to collect new specimens and the clinical data was de-identified, so the consent was waived by IRB of Children’s Hospital of Hebei Province. After obtaining the IRB’ permission, we can review patient records and use these data, which were all de-identified.

Consent for publication

Not applicable.

Competing interests

All the authors declared that they have no competing interests.


  1. 1.
    Tang VL, Halm EA, Fine MJ, Johnson CS, Anzueto A, Mortensen EM. Predictors of rehospitalization after admission for pneumonia in the veterans affairs healthcare system. J Hosp Med. 2014;9(6):379–83.CrossRefGoogle Scholar
  2. 2.
    Toledo D, Soldevila N, Torner N, Perez-Lozano MJ, Espejo E, Navarro G, Egurrola M, Dominguez A. On-behalf of the project FISPIWG: factors associated with 30-day readmission after hospitalisation for community-acquired pneumonia in older patients: a cross-sectional study in seven Spanish regions. BMJ Open. 2018;8(3):e020243.CrossRefGoogle Scholar
  3. 3.
    Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68(11):1057–65.CrossRefGoogle Scholar
  4. 4.
    Capelastegui A, Espana Yandiola PP, Quintana JM, Bilbao A, Diez R, Pascual S, Pulido E, Egurrola M. Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. Chest. 2009;136(4):1079–85.CrossRefGoogle Scholar
  5. 5.
    Dong T, Cursio JF, Qadir S, Lindenauer PK, Ruhnke GW. Discharge disposition as an independent predictor of readmission among patients hospitalised for community-acquired pneumonia. Int J Clin Pract. 2017;71(3–4):e12935.CrossRefGoogle Scholar
  6. 6.
    Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis. 2008;46(4):550–6.CrossRefGoogle Scholar
  7. 7.
    Adamuz J, Viasus D, Camprecios-Rodriguez P, Canavate-Jurado O, Jimenez-Martinez E, Isla P, Garcia-Vidal C, Carratala J. A prospective cohort study of healthcare visits and rehospitalizations after discharge of patients with community-acquired pneumonia. Respirology. 2011;16(7):1119–26.CrossRefGoogle Scholar
  8. 8.
    Brogan TV, Hall M, Williams DJ, Neuman MI, Grijalva CG, Farris RW, Shah SS. Variability in processes of care and outcomes among children hospitalized with community-acquired pneumonia. Pediatr Infect Dis J. 2012;31(10):1036–41.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Neuman MI, Hall M, Gay JC, Blaschke AJ, Williams DJ, Parikh K, Hersh AL, Brogan TV, Gerber JS, Grijalva CG, et al. Readmissions among children previously hospitalized with pneumonia. Pediatrics. 2014;134(1):100–9.CrossRefGoogle Scholar
  10. 10.
    Nakamura MM, Zaslavsky AM, Toomey SL, Petty CR, Bryant MC, Geanacopoulos AT, Jha AK, Schuster MA. Pediatric Readmissions After Hospitalizations for Lower Respiratory Infections. Pediatrics. 2017;140(2):e20160938.CrossRefGoogle Scholar
  11. 11.
    Berry JG, Toomey SL, Zaslavsky AM, Jha AK, Nakamura MM, Klein DJ, Feng JY, Shulman S, Chiang VW, Kaplan W, et al. Pediatric readmission prevalence and variability across hospitals. Jama. 2013;309(4):372–80.CrossRefGoogle Scholar
  12. 12.
    Lee KY. Pediatric respiratory infections by mycoplasma pneumoniae. Expert Rev Anti-Infect Ther. 2008;6(4):509–21.CrossRefGoogle Scholar
  13. 13.
    Nelson S, Belknap SM, Carlson RW, Dale D, DeBoisblanc B, Farkas S, Fotheringham N, Ho H, Marrie T, Movahhed H, et al. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP study group. J Infect Dis. 1998;178(4):1075–80.CrossRefGoogle Scholar
  14. 14.
    Barker CE, Sillis M, Wreghitt TG. Evaluation of Serodia Myco II particle agglutination test for detecting mycoplasma pneumoniae antibody: comparison with mu-capture ELISA and indirect immunofluorescence. J Clin Pathol. 1990;43(2):163–5.CrossRefGoogle Scholar
  15. 15.
    Templeton KE, Scheltinga SA, Graffelman AW, Van Schie JM, Crielaard JW, Sillekens P, Van Den Broek PJ, Goossens H, Beersma MF, Claas EC. Comparison and evaluation of real-time PCR, real-time nucleic acid sequence-based amplification, conventional PCR, and serology for diagnosis of mycoplasma pneumoniae. J Clin Microbiol. 2003;41(9):4366–71.CrossRefGoogle Scholar
  16. 16.
    Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, Matsuoka M, Kenri T, Arakawa Y, Sasaki T. Clinical evaluation of macrolide-resistant mycoplasma pneumoniae. Antimicrob Agents Chemother. 2006;50(2):709–12.CrossRefGoogle Scholar
  17. 17.
    Wang L, Feng Z, Zhao M, Yang S, Yan X, Guo W, Shi Z, Li G. A comparison study between GeXP-based multiplex-PCR and serology assay for mycoplasma pneumoniae detection in children with community acquired pneumonia. BMC Infect Dis. 2017;17(1):518.CrossRefGoogle Scholar
  18. 18.
    Wang L, Zhao M, Shi Z, Feng Z, Guo W, Yang S, Liu L, Li G. A GeXP-based assay for simultaneous detection of multiple viruses in hospitalized children with community acquired pneumonia. PLoS One. 2016;11(9):e0162411.CrossRefGoogle Scholar
  19. 19.
    Driscoll AJ, Karron RA, Morpeth SC, Bhat N, Levine OS, Baggett HC, Brooks WA, Feikin DR, Hammitt LL, Howie SRC, et al. Standardization of Laboratory Methods for the PERCH Study. Clin Infect Dis. 2017;64(suppl_3):S245–52.CrossRefGoogle Scholar
  20. 20.
    Marks C, Loehrer S, McCarthy D. Hospital readmissions: measuring for improvement, accountability, and patients. Issue brief. 2013;24:1–8.PubMedGoogle Scholar
  21. 21.
    Andruska A, Micek ST, Shindo Y, Hampton N, Colona B, McCormick S, Kollef MH. Pneumonia pathogen characterization is an independent determinant of hospital readmission. Chest. 2015;148(1):103–11.CrossRefGoogle Scholar
  22. 22.
    Toomey SL, Peltz A, Loren S, Tracy M, Williams K, Pengeroth L, Ste Marie A, Onorato S, Schuster MA. Potentially Preventable 30-Day Hospital Readmissions at a Children's Hospital. Pediatrics. 2016;138(2):e20154182.CrossRefGoogle Scholar
  23. 23.
    Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004;17(4):697–728 table of contents.CrossRefGoogle Scholar
  24. 24.
    Williams DJ, Hall M, Brogan TV, Farris RW, Myers AL, Newland JG, Shah SS. Influenza coinfection and outcomes in children with complicated pneumonia. Arch Pediatr Adolesc Med. 2011;165(6):506–12.CrossRefGoogle Scholar
  25. 25.
    Brogan TV, Hall M, Sills MR, Fieldston ES, Simon HK, Mundorff MB, Fagbuyi DB, Shah SS. Hospital readmissions among children with H1N1 influenza infection. Hosp Pediatr. 2014;4(6):348–58.CrossRefGoogle Scholar
  26. 26.
    Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med. 2002;162(11):1278–84.CrossRefGoogle Scholar
  27. 27.
    Auerbach AD, Kripalani S, Vasilevskis EE, Sehgal N, Lindenauer PK, Metlay JP, Fletcher G, Ruhnke GW, Flanders SA, Kim C, et al. Preventability and causes of readmissions in a National Cohort of general medicine patients. JAMA Intern Med. 2016;176(4):484–93.CrossRefGoogle Scholar
  28. 28.
    Gay JC, Hain PD, Grantham JA, Saville BR. Epidemiology of 15-day readmissions to a Children's hospital. Pediatrics. 2011;127(6):e1505–12.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Institute of Pediatric Research, Children’s Hospital of Hebei ProvinceShijiazhuangChina
  2. 2.Hebei General HospitalShijiazhuangChina
  3. 3.No.2 Department of RespiratoryChildren’s Hospital of Hebei ProvinceShijiazhuangChina

Personalised recommendations